Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gavin Andrews is active.

Publication


Featured researches published by Gavin Andrews.


Biomacromolecules | 2008

Physicochemical characterization of bioactive polyacrylic acid organogels as potential antimicrobial implants for the buccal cavity.

David Jones; Brendan C.O. Muldoon; A. David Woolfson; Gavin Andrews; F.Dominic Sanderson

This study describes the formulation and physicochemical characterization of poly(acrylic acid) (PAA) organogels, designed as bioactive implants for improved treatment of infectious diseases of the oral cavity. Organogels were formulated containing a range of concentrations of PAA (3-10% w/w) and metronidazole (2 or 5% w/w, representing a model antimicrobial agent) in different nonaqueous solvents, namely, glycerol (Gly), polyethylene glycol (PEG 400), or propylene glycol (PG). Characterization of the organogels was performed using flow rheometry, compressional analysis, oscillatory rheometry, in vitro mucoadhesion, moisture uptake, and drug release, methods that provide information pertaining to the nonclinical and clinical use of these systems. Increasing the concentration of PAA significantly increased the consistency, compressibility, storage modulus, loss modulus, dynamic viscosity, mucoadhesion, and the rate of drug release. These observations may be accredited to enhanced molecular polymer entanglement. In addition, the choice of solvent directly affected the physicochemical parameters of the organogels, with noticeable differences observed between the three solvents examined. These differences were accredited to the nature of the interaction of PAA with each solvent and, importantly, the density of the resultant physical cross-links. Good correlation was observed between the viscoelastic properties and drug release, with the exception of glycerol-based formulations containing 5 and 10% w/w PAA. This disparity was due to excessive swelling during the dissolution analysis. Ideally, formulations should exhibit controlled drug release, high viscoelasticity, and mucoadhesion, but should flow under minimal stresses. Based on these criteria, PEG 400-based organogels composed of 5% or 10% w/w PAA exhibited suitable physicochemical properties and are suggested to be a potentially interesting strategy for use as bioactive implants designed for use in the oral cavity.


Pharmaceutical Technology Europe | 2009

Hot Melt Extrusion: An Emerging Drug Delivery Technology

Gavin Andrews; David Jones; Daniel N. Margetson; M. McAllistar; Osama Abu Diak


European Journal of Parenteral & Pharmaceutical Sciences | 2010

Hot-Melt Extrusion Technology: optimising drug delivery

Mathew Williams; David Jones; Yiwei Tian; Gavin Andrews


Archive | 2011

Multi-layered Device

Gavin Andrews; David Jones; Sean Gorman


Modern Mucosal Vaccines, Adjuvants and Microbicides | 2010

Developmental formulations and vaginal mucosal delivery of a recombinant HIV-1 calde-C trimeric gp140 envelope glycoprotein induces specific serum and mucosal antibody responses

Rhonda Curran; Louise Donnelly; Ryan Morrow; C. Fraser; John S. Tregoning; Gavin Andrews; Karl Malcolm; David Woolfson; Robin J. Shattock; Martin Cranage


Archive | 2009

An implantable medical device with ph sensitive layers

Gavin Andrews; David Jones; Sean Gorman


Liposomes advances: progress in drug and vaccine delivery | 2009

Development of liposome-based freeze-dried rods for vaginal immunization against HIV-1 infection

Karl Malcolm; Prem N. Gupta; Rhonda Curran; Gavin Andrews


British Pharmaceutical Conference | 2009

Formulation of HIV-1 clade C Envelope Protein CN54gp140 into Directly Compressed Solid Dosage Forms as a Potential Delivery System for Vaginal Mucosal Vaccination

Ryan Morrow; Louise Donnelly; Karl Malcolm; Rhonda Curran; Gavin Andrews; David Woolfson


5th Annual Grand Challenges in Global Health Meeting | 2009

Vaginal delivery of a recombinant HIV-1 clade-C trimeric gp140 within rheologically structured vehicles induces specific immune responses

Rhonda Curran; Louise Donnelly; Ryan Morrow; Gavin Andrews; Karl Malcolm; David Woolfson; Frank Wegmann; Quentin J. Sattentau; Martin Cranage; C. Fraser


5th Annual Grand Challenges in Global Health Meeting | 2009

Novel vaginal formulation strategies for the induction of HIV-1-specific immune responses following intravaginal mucosal immunisation

Rhonda Curran; Louise Donnelly; Ryan Morrow; C. Fraser; Gavin Andrews; Martin Cranage; Karl Malcolm; David Woolfson; Robin J. Shattock

Collaboration


Dive into the Gavin Andrews's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Louise Donnelly

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Rhonda Curran

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Ryan Morrow

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Sean Gorman

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge